Healthcare Finance News October 21, 2024
Respondents say they are strongly considering not stocking the drugs because of potential low reimbursements from PBMs.
A new national survey shows more than 90% of independent pharmacists may not sell drugs for which the Medicare Part D program is trying to negotiate lower prices. If they don’t, the administration’s effort to reduce prescription drug prices is bound to fail, according to the National Community Pharmacists Association.
The administration announced in August a list of 10 drugs for which the Medicare Part D program will seek to negotiate lower prices. They include drugs for diabetes, blood clots, heart disease and other conditions.
The drugs subject to the new pricing include Januvia; Farxiga; Enbrel; Jardiance; Setalara; Xarelto; Eliquis; Entresto; Imbruvica;...
Today's Sponsors
Today's Sponsor